News
Syndesis Health and InSyBio Partner in Predictive Modelling and Biomarker Discovery
InSyBio, a leading biotechnology company that has developed a suite of advanced AI tools for biomarker discovery in clinical and multi-omics data, has announced a strategic partnership with Syndesis Health, a leader in global real-world evidence. The partnership aims to leverage the clinical and genomic data on Syntium, Syndesis’ data platform of global healthcare data, to accelerate… Continue reading→
InSyBio Suite Version 3.1 is released facilitating interactive and efficient network and machine-learning driven multi-omics data analysis
An increasing number of pharma and academic labs are getting access to multi-omics and multi-modal datasets. However, their processing requires multiple tools, while network analytics and data visualization can become challenging considering the high dimensionality, complexity and the presence of mutual information among different omics technologies. Moreover, predictive analytics using multi-omics data suffers from the… Continue reading→
Fitly Health & InSyBio have partnered to create the world’s first Metabolic AI™ precision nutrition program for metabolic syndrome, prediabetes, and Type 2 diabetes
Fitly Health has partnered with InSyBio to deliver life-changing outcomes for patients and employees with metabolic disorders who need to lose weight. Everyone has a unique metabolism and research now shows that our metabolic health is largely affected by diet-influenced changes to our gut microbiome. In other words, existing dietary interventions would be more effective in… Continue reading→
Understanding Taste by Studying the Protein-Protein Interactions of Taste Receptors
Understanding the underlined cellular mechanisms of human taste is an essential step for designing new food products and for improving the taste of food, nutraceutical, food supplements and even pharmaceutical products. Moreover, taste mechanisms have been evolutionary linked with protective mechanisms against hazardous compounds, thus understanding how taste works at a molecular level and its… Continue reading→
InSyBio enters Loyal VC investment Stage 2 and initiates the next financing round
In April 2023, InSyBio entered the second investment stage of the Loyal VC program and will receive follow-up funding from the Toronto, Canada-based international fund with active partnerships with Founder Institute and INSEAD. This funding will be part of InSyBio’s ongoing Series A financial round of a total of 2,000,000 Euros, with Loyal VC further assisting in… Continue reading→
InSyBio facilitates food design through an interpretable Umami taste predictor
InSyBio, through its participation in the Virtuous Project together with a prestigious team of researchers and industry players, has recently contributed to the implementation of the Virtuous Umami tool, a tool which can accurately predict the umami taste. This machine learning-based tool was tested against five databases related to foods or natural compounds and demonstrated… Continue reading→
A new tool for processing single cell RNA-sequencing data
Single-cell RNA-sequencing is a genomic approach for the detection and quantitative analysis of RNA molecules in biological samples and has been extremely successful in the past few years in studying the cell-composition of biological samples, exploring cell proliferation and cell migration mechanisms and providing another layer of information in addition to bulk-RNA sequencing technologies.The new… Continue reading→
Mass Spectrometry Proteomics Data : From raw data to discovery
October 7, 2021 (7:00 PM – 8:00 PM EEST) Introduction to experimental and computational mass spectrometry proteomics pipelines for biomecial application and discovery of biomarkers. Mass spectrometry-based proteomics is a strong tool for the proteome of biosamples and has numerous applications for the discovery of diagnostic, prognostic and therapeutic biomarkers. However, there exist several different… Continue reading→
Optimized and automatized biomarker discovery and processing of biomedical data with InSyBio Pipelines
The new version of InSyBio Suite includes InSyBio Pipelines, a new tool for automatizing and optimizing the computational process for identifying biomarkers. The CEO of InSyBio, Labros Digonis, stated that “This new version of InSyBio Suite overcomes some major limitations of biomedical big data analytics and biomarker discovery and opens the road to establish it as the… Continue reading→
Personalizing the treatment of Chronic Pain Patients using the Salonpas® Pain Relieving Patch and Interpretable Artificial Intelligence
Traditionally, prescribed opioid analgesics for treating Chronic Pain can become harmful for the patients and negatively affect their lives. In the meantime, the Chronic Pain condition is affecting the lives of millions of patients deteriorating their ability to perform everyday tasks, diminishing their performance in their work environment and, in general, reducing their satisfaction of… Continue reading→